Nkarta, Inc.

NKTX

Held by 1 specialist biotech fund

Share on X

Fund Holdings

RA Capital Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management16.2%May 2, 2022

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 10,805,129Value: $20.0M

# Signal Note: RA Capital initiates $20M position in Nkarta (NKTX) RA Capital's $20M entry into NKARTA signals conviction in the company's engineered NK cell platform, likely driven by upcoming catalysts in its lead programs—NKX101 for relapsed/refractory AML and NKX019 for B-cell malignancies. Given RA Capital's track record in pre-revenue biotech bets, this suggests confidence in clinical readouts or partnering potential within 12-18 months. The position size (~$20M) indicates selective conviction rather than major portfolio concentration.

More NKTX Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SLDB1 fund SION1 fund SPRY1 fund ABOS1 fund TSHA1 fund PCSC1 fund RNA1 fund QGEN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: